

Allan Danroth
17303 108 Ave NW
Edmonton, Alberta T5S 1G2
780-483-2783
General Intermediates of Canada Inc.
news@generalintermediates.com

FOR IMMEDIATE RELEASE: 07/13/15

General Intermediates of Canada Sold to Local Alberta Investors

Edmonton Pharmaceutical Manufacturer Looks to Grow and License Previously Unreleased Technologies

General Intermediates of Canada, a little known pharmaceutical manufacturer headquartered in Edmonton, has been sold to a group of local private investors. The transaction was completed in December 2014, according to spokesman Allan Danroth.

“We are very excited about this acquisition. GIC has been in operation for over 30 years, manufacturing and supplying pharmaceutical intermediates for some of the biggest players in the industry. This small gem of a company is sitting on a wealth of previously undisclosed and unpublished information that is truly unique on a global level.” said Danroth.

“The proprietary work of its founder, Dr. Mordechai Kleiner, is nothing short of cutting edge. The processes he developed allows for the modification of molecules in ways previously not thought possible and which – in some cases – defy published literature.”

“The technology developed by GIC has enabled the company to produce intermediates that are used in things like asthmatics, chemotherapeutics, pain-medication for MS patients and the production of B-Thymidine for use in HIV medication.”

Executive VP of Technology, Dr. Glenn Weagle, will lead the science and research work at GIC. “Dr. Kleiner’s work was highly focussed on low temperature synthesis, particularly as it relates to purine, pyrimidine and nucleosides. In lay terms, what this work does is allows us to produce intermediates that are of higher quality, higher purity, higher stability, and at lower cost, than our competitors. In some cases, these techniques allow us to manipulate the rings of the molecule, allowing for substitution of one group for another, in a way unique to GIC. We are able to produce molecules that few others in the world can produce.”

“We have a great Board in place and plan to grow the company aggressively,” said Danroth. “We are now focussed on entering into partnership and licensing arrangements with other pharmaceutical companies. We want to get the work of Dr. Kleiner off the shelf and out to the pharmaceutical community where it belongs. At the same time, we are looking at Dr. Kleiner’s work on molecule modification and determining how it can be applied to other industries like agriculture, veterinary medicine and the oil & gas industry.”

About General Intermediates of Canada Inc.: GIC is a boutique provider of small molecules to the pharmaceutical industry. The company’s main business is the research and production of small batch quantities of unique organic bio-molecules. The intermediates synthesized by GIC are precursors for pharmaceuticals used in research for MS, asthmatics, anti-virals, and chemotherapeutics.

About Pharmaceutical Intermediates: a pharmaceutical intermediate is a compound that is formed in a stage between the parent substance and the final pharmaceutical compound. It is a “stepping stone” in the synthesis of the final product.